---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-131064"
form_type: "8-K"
ticker: "VYNE"
cik: "0001566044"
company_name: "VYNE Therapeutics Inc."
filed_at: "2024-12-23T23:59:59+00:00"
generated_at: "2026-05-28T23:36:25.238071+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# VYNE reports positive Phase 1a MAD data for VYN202; no AE, robust biomarker activity

## Summary
- VYN202 showed favorable safety with no drug-related AEs, including no thrombocytopenia or neutropenia.
- PK supports once-daily dosing; dose-dependent exposure reached steady-state after 7 days.
- Increased target engagement biomarker HEXIM-1; inhibited Th17, Th1/myeloid, Th1/Tc inflammatory biomarkers.
- No drug-drug interaction when co-administered with methotrexate, a common treatment for immune conditions.

## SEC filing metadata
- accession: 0001104659-24-131064
- form_type: 8-K
- ticker: VYNE
- cik: 0001566044
- company_name: VYNE Therapeutics Inc.
- filed_at: 2024-12-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1566044/000110465924131064/0001104659-24-131064-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1566044/000110465924131064/tm2431817d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-131064
- JSON: https://secwatch.observer/filing/0001104659-24-131064.json
- Plain text: https://secwatch.observer/filing/0001104659-24-131064.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.